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ABSTRACT 
 
Recently, human maternal placenta ingestion, known as placentophagy, has emerged 
as a rare but growing practice among postpartum mothers in industrialized societies, and 
is currently found in both home birth and hospital birth settings. The practice is purported 
to result in certain health benefits for postpartum mothers, some of which could be 
related to the iron content in full-term placenta (e.g., increased energy and an improved 
and more rapid postpartum recovery, among others). The aim of this research project was 
to investigate the effect of encapsulated placentophagy on maternal postpartum iron 
status via a randomized, double-blind, placebo-controlled pilot study (n=28). The 
majority of participants were Caucasian (79%), with at least some college education  
(88.7%), and married or in a domestic partnership (87%). Maternal iron status of women 
in the placenta supplement group (n=12), the placebo group (n=16), and an additional 
iron-supplement comparison group (n=3) was measured via hemoglobin, transferrin, and 
ferritin taken from blood samples at four time points; the 36th week of pregnancy, within 
72 hours of parturition, between days five and seven postpartum, and during week three 
postpartum. All participants also completed a Willet Food Frequency Questionnaire in 
order to assess dietary iron intake during the study period. Results reveal no statistically 
significant differences in the maternal iron status of women in the placenta supplement 
and placebo (beef or vegetarian supplements) groups. While the small sample size of the 
additional (over-the-counter) oral iron supplement group did not allow for statistical 
comparison with the placenta supplement and placebo groups, maternal iron status of 
these participants varied only slightly from those of placenta supplement and placebo 
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group participants. The current study suggests that encapsulated placenta 
supplementation neither significantly improves, nor impairs postpartum maternal iron 
status for women consuming at least adequate amounts of dietary iron.  
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CHAPTER 1 
 
INTRODUCTION AND STUDY AIMS 
Introduction 
Recently, the practice of human maternal placenta ingestion, known as placentophagy, 
has gained popularity among mothers in industrialized societies, who cite its many 
purported health benefits.  As the practice has become more common, increasingly 
human placentophagy is spreading from natural home birth settings to hospital births. 
Advocates of this practice cite the ubiquity of placentophagy among mammals generally 
and note the hypothesized adaptive value of the behavior for mammalian mothers put 
forward by scientists (e.g., maternal pain reduction, increased milk production, and 
postpartum nutrition).  Among human mothers, this practice is purported to result in 
many benefits including increased energy, and improved and more rapid postpartum 
recovery, among others. Such benefits may be related to the iron content in full-term 
placenta (Bradley, et al., 2004). Many pregnant and postpartum women are advised by 
medical professionals to take iron supplements in order to prevent or reverse iron-
deficiency and iron-deficiency anemia (IDA) (Bodnar, Cogswell, & McDonald, 2005). 
Iron-deficiency and IDA are characterized mainly by fatigue, followed by additional 
symptoms of pallor, weakness, labored breathing, headache, palpitations, and dizziness 
(Pavord, Myers, Robinson, Allard, Strong, & Oppenheimer, 2012). Many new mothers 
choose to ingest their placenta as a “natural” alternative to hormone and nutrient 
supplements (PlacentaBenefits.info, 2015). Heme (i.e., animal sources) iron, in particular, 
may be an important component of these placenta supplements, potentially allowing 
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women an especially rapid recovery from deficiency, something currently unavailable to 
them with standard plant-based iron supplements or perhaps other forms of dietary iron 
(Pavord et al., 2012). Some placentophagic mothers have claimed their physicians noted 
an especially rapid postpartum iron rebound, and have attributed this recovery to placenta 
capsule ingestion (Young S.M., 2012). 
The placenta is a highly vascularized, iron-rich organ (Bradley, et al., 2004). 
Placentophagy advocates propose that ingesting the organ in any form (e.g. raw, cooked, 
or dried and encapsulated) will provide all of the necessary iron required for postpartum 
mothers. This research project evaluates the efficacy of such claims by means of a 
clinically controlled comparison of postpartum maternal iron status. The project was 
conducted among 3 groups: women ingesting placenta supplements, women ingesting a 
vegetable or beef-based placebo, and women ingesting traditional ferrous sulfate iron 
supplements. The results of this study provide an objective evaluation of placentophagy 
advocates’ claims of a more rapid iron rebound for postpartum women, as these claims 
have never been evaluated through rigorous scientific testing. 
 
General Aims of the Study 
Research on the emerging practice of human placentophagy can help inform pregnant 
and postpartum women about the potential benefits and risks of ingesting their placenta. 
The results of the current study may aide women in making more informed decisions 
about their own health and that of their offspring. The dominant narrative among 
placentophagy advocates revolves around the “natural” aspects and benefits of the 
practice (PlacentaBenefits.info, 2015), despite its conspicuous absence as a traditional 
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practice in contemporary human societies. Recent cross-cultural research reveals that 
while the ritual treatment/disposal of the placenta is central to many cultural beliefs and 
customs, consumption of the placenta is all but unknown.  The single ethnographic case 
of placentophagy comes from Chicano culture, likely part of the recently emerging 
practice and not evidence of traditional consumption (Young & Benyshek, 2010).  
It is important that women engaging in placentophagy know precisely what they are 
consuming. While women understand that they are ingesting placenta, there is only a 
vague idea of human placental composition. Most information women receive about this 
practice is anecdotal and provided by maternal human placentophagy proponents. 
Rigorous scientific studies can be used help to gain a clearer picture of precisely what, 
and how much they are ingesting. To date, the potential health benefits or risks of 
maternal placentophagy have not been scientifically assessed in humans. The public 
health implications may be significant. Discerning how placentophagy may effect 
maternal iron status immediately postpartum, and compared to standard over-the-counter 
oral iron supplements is especially important information for new mothers, and may be 
especially important for iron deficient or IDA women that choose to forego traditional 
over the counter (OTC) iron supplements in favor of placentophagy.  For these women, 
iron uptake via placenta capsules (over the course of several weeks) must be sufficient to 
amend iron deficits. Because iron deficiency and IDA are associated with negative health 
outcomes for mother and child, this issue is particularly important and relevant. 
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CHAPTER 2 
 
LITERATURE REVIEW 
Mammalian Placentophagy 
Maternal placentophagy, or the consumption of the placenta or afterbirth postpartum 
is a ubiquitous behavior among terrestrial mammal mothers. Nearly all of the more than 
4,000 terrestrial mammalian species consume the placenta after birth: carnivore, 
herbivore, and omnivore alike. The only exceptions are camelids, and possibly, humans.  
Recently, a very small but growing number of women in industrialized countries are 
ingesting their placentas postpartum in the belief that it will improve recovery after 
delivery, increase lactation, and protect against postpartum mood disorders, amongst 
other purported benefits (Selander, Cantor, Young, & Benyshek, 2013). Many 
placentophagy advocates have cited non-human mammalian placentophagy to justify the 
practice among human mothers (PlacentaBenefits.info, 2015). Cross-cultural instances of 
this practice in human populations, however, are exceedingly rare to non-existent; a 2010 
review of the cross-cultural literature regarding placenta treatment and disposal practices 
found no evidence of placentophagy as a longstanding traditional practice in any culture 
(Young & Benyshek, 2010). 
 Kristal and colleagues have described the most prevalent speculative explanations for 
placentophagy among mammals generally (Kristal, DiPirro, & Thompson, 2012). The 
first of these hypotheses states that, “the mother undergoes a shift in food preference 
toward carnivorousness at the time of parturition” (Kristal, 1980). A second proposes that, 
“mothers eat the afterbirth to maintain the cleanliness of the nest site and to avoid 
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attracting predators” (Kristal, 1980). While compelling, these hypotheses alone do not 
provide sufficient explanations for the practice across taxa.  
Hypothesis 3 states “that mothers consume the afterbirth because of general hunger, 
i.e., that anorexia prior to parturition leads to placentophagy as a means of maintaining 
homeostatic food intake requirements” (Kristal, 1980); and a fourth hypothesis “that 
placentophagy is a response to specific hunger, i.e., a response to specific nutritional or 
hormonal needs which can be satisfied by consuming the afterbirth” (Kristal, 1980).   
The hypothesis of general hunger applies to animals that fast prior to parturition, 
which may include humans, depending upon the culture studied. Maternal “anorexia prior 
to parturition leads to placentophagy as a means of maintaining homeostatic food intake 
requirements” (Kristal, 1980). There is also evidence of fasting among non-human 
animals (e.g. dogs, horses) prior to parturition (Kristal, 1980). 
 Finally, specific hunger occurs when nutritional deficiencies result in cravings for 
substances rich in those nutrients (e.g. iron, zinc, or calcium), hormones (e.g., oxytocin or 
progesterone) or endogenous opioid or opioid factors (e.g., placental opioid enhancing 
factor). It should be noted, however, that placentophagy among mammals is not strictly a 
maternal behavior, as the general and specific hunger hypotheses might imply. Some 
mammals, such as hamsters, consume the placenta crossing age, sex, and reproductive 
history lines (Gregg & Wynne-Edwards, 2005; Gregg & Wynne-Edwards, 2006). 
Because of the demands of pregnancy, however, postpartum mothers are more likely to 
suffer from nutritional deficiencies, and those found in the placenta may reestablish 
maternal nutritional sufficiency.  Of specific interest to this study is the micronutrient 
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iron, which is depleted through pregnancy, blood loss during the birthing process, and 
demands on the postpartum mother through lactation.  
Some women with iron deficiency or IDA experience pica, a craving for non-
nutritive substances rich in certain micronutrients. In one study conducted in South 
Africa, 10 iron deficient women were engaging in pica by ingesting dry soil and paper, 
two of whom were pregnant (Walker, Walker, Sookaria, & Cannan, 1997). Another form 
of pica known as pagophagy (ice consumption) has been correlated with iron deficiencies 
in some women, wherein pagophagy either diminishes or disappears after iron treatment 
(Young S. L., 2010). In another analysis, Young and colleagues assessed over 482 
cultural-level accounts for reports of human geophagy while additionally assessing 
accounts of 297 species that have engaged in geophagy across taxa. Ultimately they 
found that geophagy among humans is more closely associated with curbing illness from 
parasites or toxic substances, as opposed to compensating for any nutritional deficiencies 
(Young, Sherman, Lucks, & Pelto, 2011). Evidence supporting iron-related geophagy is 
controversial, as not all women engaging in the practice are iron deficient, and the 
practice among humans in general may have little to do with nutrition. Today most 
mothers in industrialized countries have easy access to iron supplements to prevent or 
treat iron deficiency during or immediately after parturition. 
 
Iron 
The placenta is a vascularized, iron-rich organ. Additionally, iron is a highly heat-
stable nutrient. Combined, these two aspects may place the modern practice of human 
! 7 
placentophagy in the unique position of providing adequate iron supplies necessary for 
postpartum women. 
Iron is also an essential nutrient. It is required for the formation of red blood cells 
(RBCs). The majority (~70%) of iron is found in hemoglobin bound to RBCs, while the 
remainder is found as transferrin produced by the liver and present in blood, or as ferritin 
stored in the liver, spleen, skeletal muscles, and bone marrow (Thompson & O'Donnell, 
2010). Iron is essential to RBCs in: a) transporting oxygen from the lungs to tissues in the 
body, and b) transferring carbon dioxide waste back to the lungs for expulsion (Erickson, 
1996). When sufficient amounts of iron stores have been depleted, iron deficiency and, 
eventually, the more severe, anemic form of iron deficiency, IDA, will result.  
There are different causes of anemia, a condition characterized by a lack of healthy 
RBCs or hemoglobin in the blood. Iron deficiency is the most prevalent cause of anemia 
and is initiated through different mechanisms (e.g. chronic or rapid bleeding, insufficient 
dietary iron intake). Sickle cell trait, malaria, HIV, certain infectious diseases, and other 
nutritional deficiencies (e.g. folate, vitamin A) may also cause anemia (Stoltzfus, 2001). 
Regardless of its etiology, the result of anemia is the same: insufficient transport of 
oxygen to tissues. 
The simplest, most accessible method for testing iron deficiency is that of 
hemoglobin concentration (for RBCs). The standard clinical cutoff value for hemoglobin 
for pregnant women is 11 g/dL, and 12 g/dL for non-pregnant women 15 years of age or 
older (World Health Organization, 2011). Blood donators are screened via this method 
for that reason; however, it has been shown that approximately 20% of donors with 
normal hemoglobin concentrations are nevertheless iron deficient (Ghosh, 2012). This is 
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known as ‘subclinical iron deficiency’. If multiple methods of measurement are not 
administered, an accurate view of iron status will not be obtained. For diagnostic and 
research purposes, medical practitioners and scientists may choose to test hemoglobin, 
serum iron, transferrin, transferrin saturation, ferritin, and total iron-binding capacity 
(TIBC), or any combination thereof (Khalafallah & Dennis, 2012). Ferritin is the storage 
form of iron, and transferrin is the transport form of iron when levels are low. Measuring 
hemoglobin, transferrin, and ferritin allows for multiple lines of evidence to determine 
iron status, as each analyte is affected by differing confounding factors. Additionally, 
hemoglobin, transferrin, and ferritin are commonly tested, due to the comparatively low 
cost of analysis and the wide availability and standardization of kits (Khalafallah & 
Dennis, 2012). One method used to assess iron deficiency is to measure three iron 
markers; if at least two of the three analytes are below expected levels, one can be 
classified as iron deficient (Cook, Finch, & Smith, 1976). 
 
Iron and Reproduction 
Pregnancy, birth, and the postpartum period are biologically demanding for women 
worldwide, across cultural and social categories. While all women are at risk, some are 
more likely to experience iron deficiency than others. For example, short inter-birth 
intervals (IBIs) and related multiparity lead to increased iron deficiency and IDA 
susceptibility. Women need time to replenish iron supplies, but short IBIs do not allow 
the time to do so. In such cases women will enter into new pregnancies already depleted, 
and by the end of the second pregnancy, iron deficiency is exacerbated (Allen, 2000). 
Additionally, obesity and a lack of exclusively breastfeeding infants at postpartum 
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checkup (meaning infants are partially or completely bottle fed) have both been identified 
as risk factors for postpartum iron deficiency and IDA, particularly among low-income 
women (Bodnar et al., 2002). The association between iron deficiency and not 
exclusively breastfeeding seems counterintuitive; however, hypotheses have been 
proposed to explain this phenomenon. Exclusive breastfeeding may extend lactational 
amenorrhea, thus preventing additional iron loss through menstruation, aiding in 
maintaining maternal iron supplies. Additionally, breastfeeding may be associated with 
women of higher Socio-Economic-Status (SES), engaging in healthier eating practices, or 
supplementation compliance (Bodnar et al., 2002). 
Research suggests that, in order to meet the demands of pregnancy, women require 
300 mg or more in iron stores prior to conception (Viteri & Berger, 2005). Women lose a 
total of 1000 mg of iron during pregnancy and lactation, resulting in the need for iron 
intake of 27 mg/day during pregnancy (Khalafallah & Dennis, 2012). The Recommended 
Dietary Allowance (RDA) for lactating women (age 19-50) is 9 mg/day (Institute of 
Medicine. Food and Nutrition Board, 2001). For women with short IBIs and multiple 
children, iron supplementation and the consumption of iron-rich and iron-fortified foods 
is of utmost importance. 
Iron deficiency and IDA can cause problems not only for the mother; there are short- 
and long-term complications for children of iron deficient mothers. Immediate problems 
from maternal anemia occur during birth when hormone function is compromised, 
leading to preterm labor and pre-eclampsia which can compromise neonatal outcomes 
(Rasmussen, 2001). Rodent studies have shown reductions in offspring birth weight, as 
well as high blood pressure at a young age (Lewis, Forhead, Petry, Oxanne, & Hales, 
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2002). One study showed that female rhesus monkeys deprived of iron during pregnancy 
produced infants with significantly lower hemoglobin, mean corpuscular volume, and 
mean corpuscular hemoglobin as compared to controls (Golub, et al., 2006). Results from 
the same study showed that prenatally iron-deprived rhesus infants exhibited reduced 
activity levels and reduced responses to new environments compared to controls, and 
infants deprived of iron postnatally exhibited poor cognitive performance and greater 
emotional reactions compared to controls (Golub, Hogrefe, Germann, Capitanio, & 
Lozoff, 2006). In humans, infants born to anemic mothers are more likely to become iron 
deficient anemic themselves (Colomer, 1990), and IDA is known to negatively affect 
mental and motor development (Allen, 2000). 
Iron deficiency is a worldwide problem, though the severity varies from country to 
country and from one ecological, political, and social context to another. According to 
data collected by the World Health Organization from 1993-2005, the global prevalence 
of anemia was 24.8% (World Health Organization, 2013). Among women of 
reproductive age, this figure increases (41.8% for pregnant women, 30.2% for non-
pregnant women) (World Health Organization, 2013). While industrialized nations 
display a lower prevalence of iron deficiency, the incidence is nevertheless high and a 
major point of concern for health officials. Iron deficiency in Western societies ranges 
from 25-40% of pregnant women, that number increasing amongst lower SES 
populations (Alwan & Cade, 2011); however, exact figures are difficult to assess due to 
the common conflation of anemia and iron deficiency anemia, which has led several 
prominent publications to inflate cases of IDA (Stoltzfus, 2001). 
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Iron and Mood 
A number of studies have linked low levels of iron to mood disorders. It is 
hypothesized that anemia, often caused by iron deficiency, increases the risk of 
experiencing mood disorders like anxiety and depression (Benton & Donohoe, 1999). 
One Australian study found a significant correlation between iron deficient women taking 
oral contraceptives and an increased probability of depression (Rangan, Blight, & Binns, 
1998). Whether this was due to iron deficiency, oral contraceptives, or a combination of 
the two is unknown. A double-blind placebo-controlled study showed a statistically 
significant correlation between iron therapy and the improved mood of 16-17 year old 
high school females (Ballin, Berar, Rubinstein, Kleter, Hershkovitz, & Meytes, 1992). A 
2003 study has linked anemia and postpartum depression: hemoglobin measurements 
taken at day seven postpartum identified eight women as anemic; by day 28, seven of 
those eight women showed signs of depression (Corwin, Murray-Kolb, & Beard, 2003). 
 
The Evolutionary Theory of IDA 
Denic and Argarwal (2007) hypothesize why iron deficiency is so prevalent among 
populations, crossing multiple social categories (e.g. countries, SES, sex, age, etc.) and 
surviving in the face of public health initiatives to eradicate iron deficiency. They begin 
by noting that iron deficiency became common in the Neolithic era with the changes 
agriculture and sedentism brought to diet. The authors then go on to propose that diseases 
humans had never been exposed to prior to sedentism and its associated crowding, caused 
iron deficiency to be favored by natural selection. Multiple lines of evidence have shown 
that iron deficiency protects against crowd diseases such as malaria, plague, and 
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tuberculosis. Sufficient iron stores are needed to prevent anemia and maintain overall 
health, however, iron can also be appropriated to fuel infectious agents. When epidemics 
occur, group selection favors those with lower levels of iron because those infectious 
agents have less nourishment from which to draw upon. In the face of such harrowing 
diseases, the authors argue, iron deficiency is the lesser evil with which the body can 
more easily cope. In a sedentary population, those who consumed iron deficient diets 
would survive more often than those who received adequate dietary iron. It is believed 
that, “multiple evolutionary factors have contributed in making iron deficiency a 
successful phenotype” (Denic & Agarwal, 2007, p. 603). Such a selective pressure might 
explain why iron deficiency and IDA are common, particularly amongst pregnant and 
postpartum women, the focus population of this study.  
Where questions of evolutionary adaptation among human populations arise, 
anthropologists often look towards modern populations of hunter-gatherers as the closest 
analog to the ancestral conditions. If iron deficiency is a byproduct of a shift in food 
procurement methods (i.e. agricultural subsistence), then one might imagine that modern 
hunter-gatherers would not suffer from iron deficiency to the extent other populations do. 
One such study of iron deficiency among the !Kung Bushmen of the Kalahari desert, 
conducted in 1971, showed a very low incidence of iron deficiency and anemia, although 
these results may have been confounded by the use of cast iron cooking pots – known to 
provide nutritional sources of iron (Metz, Hart, & Harpending, 1971). Hunter-Gatherers 
are some of the fittest of populations, exercising regularly and with access to a broad-
spectrum diet. In contrast, sedentary and semi-sedentary communities (e.g. 
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horticulturalists, agriculturalists) have far less dietary variety and suffer the most from 
nutritional deficiencies. 
 
Iron and Encapsulated Human Placenta 
In a study from 2000 conducted in Thailand, researchers analyzed 30 human (15 
female, 15 male) heat-dried placentas for hormone and nutrient content. Results show 
that heat-treated and granulated placentas contain, on average, 1.01 mg/g of iron 
(Phuapradit et al., 2000). According to recommended dosages for the first week 
postpartum, women engaging in placentophagy ingest a maximum of 3300 mg/day of 
granulated encapsulated placenta (PlacentaBenefits.info, 2015). Recall that the daily 
recommended dietary iron intake for lactating females aged 19-50 is 9mg (Institute of 
Medicine. Food and Nutrition Board, 2001). Therefore, the amount of iron found in the 
placentas in the Phuapradit et al. study represents about 1/3 of the daily recommended 
dietary iron intake (3.3 mg of iron per day in placenta supplements).  
Based on findings from the study by Phuapradit et al (2000), encapsulated placenta 
may provide 33% or more of the recommended dietary iron intake during the first week 
postpartum. Iron from meat sources (heme iron) comes in a more bioavailable form than 
vegetable sources (nonheme iron), meaning placental iron could have a greater impact 
upon dietary needs, compared to a simple nonheme iron supplement of the same dose. 
About half of the iron found in meat comes in heme form and has a higher absorption rate 
than nonheme iron. Nonheme iron is much more common in food generally, having a 
greater overall impact on iron supplies due to its sheer ubiquity. Additionally, nonheme 
iron absorption can be inhibited or increased by other dietary factors as well as existing 
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iron stores (Monson, 1988). The bioavailability of iron found in placenta may be further 
complicated by the hundreds of substances found in human placental tissue, including 
many micronutrients, peptide and steroid hormones, and endogenous opioid 
neuropeptides, among others. These substances may interact with iron and or otherwise 
affect the physiology of postpartum mothers in ways that inhibit or facilitate iron 
absorption.  
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CHAPTER 3 
 
RESEARCH QUESTIONS AND HYPOTHESES 
In order to determine whether the ingestion of placenta capsules affects iron levels of 
postpartum women, we compared iron measurements among three groups of women: one 
group ingesting typical non-heme iron tablet supplements (Iron Group), a second group 
ingesting a placebo made of either beef or vegetarian meat substitute (Placebo Group), 
and a third group ingesting their own dehydrated and encapsulated placenta 
(Experimental Group). 
Null Hypothesis 1: Experimental, Placebo, and Iron Group participants will not show 
an increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) measured 
during, (a) days five-seven postpartum, and (b) week three postpartum, as compared to 
baseline measure taken prior to supplement initiation (within 72 hours postpartum). 
Hypothesis 1: Experimental, Placebo, and Iron Group participants will show an 
increase in iron levels (assessed via hemoglobin, transferrin, and ferritin) measured 
during, (a) days five-seven postpartum, and (b) week three postpartum, as compared to 
baseline measure taken prior to supplement initiation (within 72 hours postpartum). 
Null Hypothesis 1a: Experimental Group participants will not show a greater interval 
increase in iron levels  (assessed via hemoglobin, transferrin, and ferritin) as compared 
to Placebo Group and Iron Group participants from baseline (within 72 hours 
postpartum) to day five-seven postpartum. 
Hypothesis 1a: Experimental Group participants will show a greater interval 
increase in iron levels  (assessed via hemoglobin, transferrin, and ferritin) as compared 
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to Placebo Group and Iron Group participants from baseline (within 72 hours 
postpartum) to day five-seven postpartum. 
Null Hypothesis 1b: Experimental Group participants will not show a greater interval 
increase in iron levels  (assessed via hemoglobin, transferrin, and ferritin) as compared 
to Placebo Group and Iron Group participants from baseline to week three postpartum. 
Hypothesis 1b: Experimental Group participants will show a greater interval 
increase in iron levels  (assessed via hemoglobin, transferrin, and ferritin) as compared 
to Placebo Group and Iron Group participants from baseline to week three postpartum. 
Null Hypothesis 1c: Experimental Group participants will not show a greater interval 
increase in iron levels  (assessed via hemoglobin, transferrin, and ferritin) as compared 
to Placebo Group and Iron Group participants from days five-seven postpartum to week 
three postpartum. 
Hypothesis 1c: Experimental Group participants will show a greater interval 
increase in iron levels  (assessed via hemoglobin, transferrin, and ferritin) as compared 
to Placebo Group and Iron Group participants from days five-seven postpartum to week 
three postpartum. 
The timing of each measurement is purposeful. The first measurement, taken during 
the 36th week of pregnancy, establishes a pre-supplementation iron baseline. As iron 
deficiency during pregnancy increases the likelihood of experiencing postpartum iron 
deficiency, this is an important measurement (Allen, 2000). The second measurement, 
taken within 72 hours of parturition, establishes the postpartum iron baseline, which can 
differ from the pregnancy iron baseline. Assessing iron status between days five-seven 
and during week three (days 21-27) respectively, assures that instances of rapid iron 
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uptake will be captured, as iron deficient women normally require four-six weeks to 
return to pre-pregnancy iron levels using standard iron supplementation, as well as 
capturing slower iron absorption that may occur during week three (Bodnar et al., 2002; 
Hyder, Persson, Chowdhury, Lonnerdal, & Ekstrom, 2003).  
 
Hypotheses Rationale 
Hypothesis 1 predicts that iron rebound will occur in all three groups; this is because 
postpartum iron status rebound is a normal occurrence and should be observed regardless 
of participant supplement group (SickKids, 2009). One postulated benefit of placenta 
ingestion relates to the organ’s iron content (Selander et al., 2013). It is proposed that the 
bioavailability of iron found in placenta prepared in any form (e.g. raw, fried, baked, 
grilled, blended, encapsulated, etc.) is superior to standard ferrous sulfate (iron) 
supplementation. Ferrous sulfate is composed of non-heme iron, while the placenta 
contains heme iron. The body absorbs heme iron two-three times more readily than non-
heme iron (15-35% of heme iron versus 2-20% of nonheme iron) (Pavord et al., 2012; 
Monson, 1988). The bioavailability of heme iron is generally not affected by other 
dietary factors, while diet can greatly affect the bioavailability of non-heme iron (Pavord 
et al., 2012; Young, et al., 2010). Meat of any form is a great source of heme iron and is 
accounted for in this study, along with other impacting dietary factors. Foods high in 
calcium can inhibit the bioavailability of both heme and nonheme iron. Phytates in 
cereals, and the tannins found in coffee and tea can inhibit iron absorption of nonheme 
iron. Eating foods with heme iron, as well as foods high in Vitamin C will enhance 
nonheme iron absorption (Pavord et al., 2012). 
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A majority of women engaging in placentophagy dehydrate, granulate, and 
encapsulate their placenta, resulting in a supply of placenta supplements to be ingested 
daily over a two to three week period, postpartum. One placenta encapsulation service 
recommends taking two capsules three times per day for two weeks, with each capsule 
containing 550 mg of dried placenta (PlacentaBenefits.info, 2015). One study has shown 
that dietary iron in cooked beef reduces the bioavailability of heme iron from 65% in raw 
beef, to 22% in beef cooked for 5.6 to 8.6 minutes. This study employed a fast, dry-heat 
cooking method wherein meat was prepared in a Silex clam cooker set at 200 degrees 
Celsius (392 degree Fahrenheit) (Purchas, Rutherford, Pearce, & Wilkinson, 2004). 
Placenta pills are typically prepared using low-heat methods of steaming and dehydration, 
which reach temperatures of 212 degrees Fahrenheit. As iron is a very heat-stable nutrient 
and is not exposed to high temperatures during encapsulation, iron degradation is limited 
with this method. 
A recent study suggests that iron may have a significant effect upon women who 
engage in maternal placentophagy. The study reveals that 96% of nearly 200 women who 
had previously engaged in maternal placentophagy rated their experience as either “very 
positive” or “positive,” 8% of participants listed restoring hormones/nutrients as a 
motivating factor for engaging in placentophagy, and 26% of participants reported 
increased energy, even though this was not a stated motivation for engaging in 
placentophagy (Selander et al., 2013). This is noteworthy, given that energy is associated 
with satisfactory iron stores, whereas iron deficiency is related to decreased energy, often 
manifested as reduced work capacity (Haas & Browlie, 2001).  
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CHAPTER 4 
 
METHODS 
Institutional Review Board and Institutional Biosafety Committee Approvals 
This study was approved by UNLV’s Institutional Review Board (IRB) Institutional 
Biosafety Committee (IBC). Active data collection for this study occurred between 
December 2013 and March 2015. This research project was conducted in conjunction 
with another study on the effects of human maternal placentophagy on postpartum 
recovery wherein Experimental and Placebo Groups, as well as Iron Group data were 
utilized for both studies. 
 
Confidentiality 
All information gathered in this study is kept as confidential as possible. All records 
(biological samples and written data) are being stored in a locked facility at UNLV for 
three years after completion of the study. Each participant was given a unique 
alphanumeric ID code. Questionnaires and biological samples are stored independent 
from the informed consent form to preserve confidentiality. 
 
Participant Recruitment 
Experimental and Placebo Groups 
Participants were informed of the study by either the webpage or social media pages 
for Placenta Benefits (PBi; an organization that provides placenta encapsulation 
information and services), or by word of mouth through Jodi Selander, founder of PBi, or 
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midwives and physicians with whom she works regularly. Interested women were 
provided with contact information for a research team member who could then provide 
more information and answer any questions about the study, and who could schedule the 
first meeting with the research team. 
Iron Group 
Participants in the Iron Group were informed of the study by word of mouth, and 
distribution of study fliers to various pregnancy and postpartum support groups in the Las 
Vegas Valley (e.g. La Leche League, Well Rounded Momma, etc.). Flyer distribution did 
not yield any responses, however word of mouth successfully found participants for the 
Iron Group. All three participants in this group were women familiar with the 
researchers; during the course of socializing, each participant was told about the study 
and asked if they would like to participate. 
 
Participants 
In order to participate in this study, volunteers were screened for either the 
Experimental and Placebo Groups, or the Iron Group. For the Experimental and Placebo 
Groups, volunteers were required to be healthy, pregnant females over the age of 18 who 
had decided to ingest their own placenta postpartum. Volunteers were excluded from 
participating in this study if they had experienced any serious pregnancy complications, 
ever ingested human placenta, or currently used drugs, cigarettes, or alcohol. Participants 
who had any current or chronic health conditions, or who were taking medications during 
pregnancy were required to discuss their decision to ingest their placenta postpartum with 
their medical practitioner and to confirm that the practitioner had not advised against 
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placentophagy in order to participate in the study.  For the Iron Group, participants were 
required to be healthy, pregnant females over the age of 18 who had decided not to ingest 
their own placenta postpartum. Iron Group participants were excluded from participating 
in this study if they had experienced any pregnancy complications, were planning to 
ingest their placenta postpartum, currently used drugs, cigarettes, or alcohol, took any 
medications, or had a medical condition that affects iron status (e.g., hemochromatosis, 
thalassemia). Some participants had a medical condition that did not necessarily exclude 
them from the study. In such cases, participants signed a form indicating they had spoken 
with their medical doctor or midwife and that they were not advised against participating 
in the study. 
 
Procedures 
Experimental and Placebo Groups 
After the initial screening and providing informed consent, participants in the 
Experimental and Placebo Groups met with two female research team members a total of 
four times in the home of the participant or in a few select cases, in a secure lab on the 
campus of UNLV. 
The first meeting occurred during the 36th week of pregnancy where the participant 
completed a background information questionnaire and provided a blood sample. 
Approximately 600µl of blood was collected through a finger-stick blood draw into a 
Sarstedt Multivette 600 capillary blood collection lithium heparin tube. An additional 
30µl (15µl x 2 measurements) of this blood was collected onto a STAT-Site MHgb test 
strip and placed in the STAT-Site MHgb meter for hemoglobin analysis. For biological 
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sample collection, researchers wore the following personal protective equipment: gloves, 
laboratory coat, and protective glasses.  
The second meeting occurred within 96 hours postpartum where the participant’s 
placenta was steamed, dehydrated, pulverized and encapsulated by a trained specialist, 
and the participant provided a blood sample. At this meeting, participants were instructed 
to ingest a postpartum supplement following a designated dosing schedule of two 550mg 
capsules three times per day for days 1-4, two 550mg capsules two times per day for days 
5-12, and two 550mg capsules once per day for days 13-21. The supplement was either 
their own dehydrated and encapsulated placenta, or placebo capsules made of either 
organic, grass-fed beef, or soy-free vegetarian meat substitute (Quorn Meatless & Soy-
Free Grounds). Prior to recruitment, identification codes were generated for each of the 
anticipated participants in the Experimental and Placebo Groups and group assignments 
were randomly generated for each participant using an online randomization generator 
(http://www.randomization.com/). This was done by the Principle Investigator, Dr. 
Daniel Benyshek, who also created sealed envelopes for each identification code that 
indicated which treatment they would receive, and was opened by the encapsulation 
specialist (Jodi Selander, Marcy Webb, or Romina Lizaso) after the placenta was 
prepared, indicating to her whether to leave the placenta or placebo capsules with the 
participant. Dr. Benyshek and the encapsulation specialists had no additional contact with 
participants once the group assignment had been revealed. None of the research team 
members who met with the participants throughout the study were aware of the 
participant’s group assignment until the conclusion of that individual's participation. 
Information about group assignment was maintained by Dr. Benyshek and was not 
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accessible to other members of the research group. The assigned set of capsules (either 
placenta or placebo) remained with the participant, while the second set was returned by 
researchers to the lab at UNLV. A seal was created with a unique code sequence that 
would be easily recognized by the participant, while simultaneously preserving their 
anonymity, as this code was independent of the participant's ID code used for the study.  
The label with the unique code was affixed over the lid of the jar of capsules that was 
stored in the lab at UNLV. This was done in order to ensure that upon return of the 
placenta capsules to a participant in the Placebo Group, she would be able to identify that 
the capsules being returned were in fact her capsules. Labeled capsules were stored in a 
locked freezer, in a locked laboratory, in a locked hallway at UNLV.  
The third meeting occurred between the fifth and seventh day postpartum where the 
participant completed a questionnaire about their dietary intake over the last year, and 
provided a blood sample.  
The fourth and final meeting occurred during the third week postpartum (days 21-27) 
where participants provided a blood sample. At the conclusion of this meeting the 
participant was debriefed and her group assignment was revealed. If she was in the 
placebo group, her placenta capsules were returned to her at this time. Participants were 
able to identify their capsules by the unique coded sticker affixed over the lid and written 
in their handwriting. 
Iron Group 
Procedures for the Iron Group were identical to the Experimental and Placebo Group 
with the exception of the following: during the second meeting (between day 5 and 7 
postpartum), participants were instructed to ingest one 65 mg postpartum iron supplement 
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(Nature’s Bounty 325 mg Ferrous Sulfate) once a day in the morning with a meal 
(Stoltzfus & Dreyfuss, 1996; Hyder et al., 2003; Khalafallah & Dennis, 2012; Viteri & 
Berger, 2005) for the duration of their participation in the study. 
 
Compensation 
Experimental and Placebo Groups 
Direct interaction between study participants and researchers occurred over the course 
of four separate occasions (approximately 60-90 minutes per meeting). Participants were 
compensated for their time with an $80 gift card to their choice of Target or Whole Foods 
at the conclusion of their participation in the study. To compensate participants for their 
time at the third meeting, they were provided with their choice of the following: 
housecleaning services, meal delivery, grocery delivery, doula services, or a consultation 
with a lactation counselor. Additionally, placenta encapsulation services were provided at 
no cost (approximate value of $300). When a participant withdrew prior to completion of 
the study, they received compensation on a pro-rated basis based on the number of 
meetings completed prior to withdrawal: a gift card in the amount of $20 per meeting 
completed. Participants were provided with their encapsulated placenta if the placenta 
had been processed prior to withdrawal. If withdrawal occurred after the third meeting, 
the selected service was also provided. 
Iron Group 
As with the Experimental and Placebo Groups, direct interaction between Iron Group 
participants and researchers occurred on four separate occasions (approximately 60 
minutes per meeting). Participants were compensated for their time with an $80 gift card 
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to their choice of Target or Whole Foods. No participants withdrew prior to the 
completion of their participation in the study. 
 
Questionnaires 
A number of questionnaires were administered to evaluate changes in participants’ 
feelings and experiences during pregnancy and postpartum, and are included in the 
broader study that evaluates the effects of placentophagy in postpartum women. The 
Background Questionnaire was administered at Meeting 1 (see appendix), and the Willet 
Food Frequency Questionnaire (FFQ) (Willet, et al., 1985) was administered at Meeting 
3 (day five-seven postpartum) and collected at Meeting 4 (week three postpartum).  
Willet Food Frequency Questionnaire 
This questionnaire was administered to participants at the third meeting and collected 
at the fourth meeting. The extensive nature and lack of temporal sensitivity of the Willet 
FFQ compelled us to allow participants to complete the questionnaire at their leisure 
between Meetings 3 and 4. The Willet FFQ averages the overall dietary intake of the 
participant over the last year.  
The iron content for each food item on the questionnaire was assessed in milligrams 
and obtained from the USDA National Nutrient Database for Standard Reference Release 
27 (United States Department of Agriculture, 2015). The most accurate and acceptable 
food for each item was chosen. In some cases, multiple foods were listed for a single 
entry (e.g. peach, apricot, or plum); in such cases, each item’s iron content was 
investigated and the food item with the highest iron content and controlling for portion 
size was chosen. It is important to note that dietary iron may be overcompensated using 
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this method. In a few rare cases, an item was not listed on the USDA Database. In such 
cases, the search engine google.com was utilized to find an appropriate representation of 
the item (e.g. the most popular or ubiquitous brand). For example, Coffee-Mate was 
selected to represent non-dairy coffee whitener. When possible, unfortified foods were 
chosen before fortified items. If a participant accidentally picked more than one 
frequency for a food item, the more frequent option was chosen. If she failed to select a 
frequency, the food was not included in the assessment. 
The iron content for each supplement on the questionnaire was assessed in milligrams. 
Using the specific supplement information obtained from the Willet FFQ and the 
Background Questionnaire, exact supplementary iron intake was ascertained. In the few 
cases where a participant failed to provide a frequency for a particular supplement, a 
frequency of once per day was assumed. Utilizing these methods of assessment the 
average daily iron intake of each participant was ascertained.  
Frequencies in the Willet FFQ were provided to participants as a range; for the 
purpose of accurate calculations, a single figure was chosen (e.g. 2-4 times per week 
became 3 times per week). To calculate a daily dietary iron intake, a total annual dietary 
iron intake was generated. The x amount of mg/Fe for each item was compared to its 
ingestion frequency, and an annual figure was generated in this way. For example, one 
egg contains 0.88 mg/Fe. The following is a formula for daily iron intake if a participant 
consumes one egg once per week: (0.88 mg * 1 per week * 4 weeks * 13 months)/364 
days = 0.12 mg/day. That participant, on average, receives 0.12 mg/day of iron from egg 
consumption. Equations include 13 months (as opposed to 12) to account for the days in 
excess of 28 missed every month using this formula. This provides an estimate up to 364 
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days, just one day short of a year. Each item’s annual estimate was calculated in this 
manner, and each item was combined for an annual iron consumption total for each 
participant; that figure was then divided by 364 (days) in order to gain an average daily 
iron ingestion estimate. 
The Willet FFQ aids in accounting for iron fluctuations due to dietary factors 
unrelated to iron, placenta, and placebo (beef or vegetarian) supplement ingestion. 
Categorizing the iron intake of participants in this way allows these factors to be cross-
referenced with biological assays (hemoglobin, transferrin, and ferritin levels measured in 
participant blood and plasma), to assure that measured iron levels were not distorted by 
dietary factors. 
Iron intake status was assigned to one of three groups based upon iron Recommended 
Dietary Intakes for lactating women between 19-50 years old (Trumbo, Yates, Schlicker, 
& Poos, 2001). Participants under the daily Recommended Dietary Allowance of 9 
mg/day were categorized as below, participants between 9-45 mg/day were categorized as 
adequate, and participants exceeding the daily allowance of 45 mg/day were categorized 
as exceeds. 
 
Placenta and Placebo Supplement Processing and Encapsulation 
Jodi Selander is the founder of the Las Vegas based organization Placenta Benefits, 
LTD, a company that provides placenta encapsulation service to women in their own 
home after giving birth. Selander, or one of her encapsulation specialists (Webb and 
Lizaso), processed and encapsulated participants' placentas, in accordance with 
Occupational Safety and Health Administration (OSHA) and Environmental Protection 
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Agency (EPA) guidelines, in the home of the participant, using the Placenta Benefits 
proprietary method in which the placenta is steamed with herbs, dehydrated, pulverized, 
and encapsulated. The placenta was collected by the midwife or doctor at the birth and 
left with the participant if she delivered at home, or transported to the home by the 
participant if she delivered in a hospital. The encapsulation specialist met with the 
participant in her home where she rinsed the organ with water, steamed it with herbs 
added to the steaming water, and dehydrated the organ overnight. Once the placenta was 
completely dehydrated, it was then pulverized using a food processor and plant-based, 
non-gelatin capsules were filled with the dehydrated tissue to create the placenta capsules 
that were given to the participant. The technique follows OSHA and EPA guidelines for 
safe handling and disinfection and ensures that the placenta did not come into contact 
with another individual's placenta, as each placenta was processed and prepared in the 
participant's home using sanitized equipment.  
The placebo capsules were prepared by a research team member, Sharon Young, at 
UNLV following identical methods to the processing and encapsulation of the placenta, 
with the exception of using herbs in the steaming water. Placebo capsules were prepared 
using either organic, free-range beef or a soy-free vegetarian ground beef substitute 
(Quorn brand Meatless & Soy-Free Grounds). Organic, free-range beef was used in order 
to reduce the presence of exogenous hormones in the meat-based placebo supplement, 
while maintaining a consistency that is similar to that of the placenta capsules. The 
vegetarian option was offered for participants who practiced a vegetarian diet or preferred 
a supplement that was not beef-based, and the meatless ground beef substitute was 
selected as the vegetarian option in order to maintain a similar consistency to that of the 
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placenta capsules. Three participants chose the vegetarian placebo, while the remainder 
(n=13) chose the beef placebo. 
 
Assessment of Iron Status 
Iron status was assessed via hemoglobin, transferrin, and ferritin levels in participant 
blood samples (Santo, 2012; Denic & Agarwal, 2007; Khalafallah & Dennis, 2012). 
Blood samples were typically collected in the late morning toward the end of each 
meeting, however the timing of sample collection varied for some participants. Blood 
samples were collected in the evening for three meetings (twice for one participant, once 
for another participant), and several samples were collected in the early morning or early 
afternoon.  
Some studies have shown that blood samples collected via capillary action 
overestimate hemoglobin levels in the high range and underestimate hemoglobin levels in 
the low range, when compared to standard venous samples (Cable, et al., 2012). Other 
studies show more generally that capillary hemoglobin values are greater than venous 
levels (Patel, Wesley, Leitman, & Bryant, 2013). For this study, our use of the point of 
care (POC) tool, STAT-Site hemoglobin meter, prevents us from encountering this issue 
for hemoglobin. Expected Values for this POC instrument establish the expected values 
for adult females as 11.0-18.0 g/dL (Stanbio Laboratory, 2013). Hemoglobin was 
measured onsite using the portable STAT-Site MHgb meter, which has a total precision 
coefficient of variation (CV) of 2.9% - 4.2%, and a within run precision CV of 3.5% - 
4.9% (Stanbio Laboratory, 2012). In the majority of cases, two blood spots were 
collected allowing us to calculate an average. In some cases the figures varied, but this 
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was normally due to collection error wherein drops of blood did not both meet the 
recommended 12µL required for the meter. Reference value ranges for this project are 
based upon the STAT-Site hemoglobin Expected Values of 11-18 g/dL. 
ZRT Laboratory (Beaverton, Oregon) analyzed transferrin and ferritin via 
immunoassay of plasma taken from finger-stick capillary samples. Siemens ELISA kits 
for transferrin and ferritin were used, with the following expected values: transferrin: 
202-364 mg/dL, and ferritin (Women 17-60 years): 13-150 mg/mL (Aquilani, et al., 
2014; Eaton, 2013). The threshold values used in this analysis for transferrin and ferritin 
are based upon venous blood samples rather than capillary blood samples (capillary being 
the method of collection used in this study). For the purposes of this study we are 
comparing between groups, therefore minor (3-7%) fluctuations of the exact values will 
not affect the comparisons made (Mejia & Viteri, 1983; Lu, Lynch, Cook, Madan, & 
Bayer, 1987).  
 
Statistical Measures 
Using SPSS version 21, the following statistical measures were conducted: Mixed 
ANOVA, with sphericity adjustment where necessary (e.g., the Greenhouse-Geisser 
estimate), tested within- and between-subjects factors simultaneously. Mixed ANOVAs 
were also conducted controlling for dietary iron status (i.e., based on categories below, 
adequate or exceeds recommended intake). 
Pearson’s r calculated correlations among dependent variables (i.e. hemoglobin, 
transferrin, and ferritin) within each time period (Meetings 1 through 4). Fluctuations 
were analyzed within the Experimental Group and the Placenta Group and then compared 
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between groups. Given the small sample size of the Iron Group (n=3), data for that 
condition are assessed as a case study, as they cannot be statistically evaluated alongside 
Experimental and Placebo Group data. 
For the small number of data points missing, data from a participant’s previous time 
period were carried forward to fill in missing data (i.e. Meeting 2 for participant PL-1012, 
and Meeting 4 for participant PL-1017).  
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CHAPTER 5 
 
RESULTS 
Initial recruitment of the study had three participants in the Iron Group and 36 
participants in the Experimental and Placebo Groups. Eight participants withdrew or were 
dropped from the study, and one participant switched from the Experimental and Placebo 
Group to the Iron Group after the first meeting. Only one participant withdrew from the 
study after initiation of supplementation, due to fear of a bad reaction to the placenta 
capsules (e.g. participant felt weepy and hormonal), however after withdrawal, it was 
discovered that she was a participant in the Placebo Group. This means that there was no 
group-based bias in dropouts due to placenta or placebo ingestion. 
The following is a breakdown of participants included in final analyses for each test 
group: (1) Experimental Group: (n=12), and (2) Placebo Group: (n=16). Iron Group 
(n=3) will be examined separately. 
 
Participant Demographics 
The women who participated in this study were an average age of 30 years old, with 
the majority Caucasian (77.4%). Most participants had an education of at least some 
college or more (83.9%); with almost equal amounts of women having attended some 
college, and earning Bachelors and Masters degrees. Fifty-five point two percent had a 
household income of at least $50,000 a year; 17.2% of participants earned between 
$20,000 and $30,000 (the lowest household income bracket selected by participants). 
According to a 2014 Demographic Report, the median household income for Las Vegas 
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was $45,670, and $47,270 for Clark County, Nevada (City of Las Vegas Economic and 
Urban Development Department & Redevelopment Agency, 2014). The majority of 
participants were married or in a domestic partnership (87%) (see Table 1).  The 
demographic profile of participants in the current study is largely consistent with that of 
other published studies of women who have engaged in maternal placentophagy in the 
past (Selander et al., 2013). 
 
Demographic Characteristics 
 Frequency % 
Age (N = 31; mean = 30) 
Ethnicity (N = 31)  
 African American 2 6.5% 
 Caucasian 24 77.4% 
 Hispanic/Latina 4 12.9% 
 Mixed: American Indian/Alaska 
Native, Caucasian 1 3.2% 
Education (N = 31) 
 High School or equivalent 1 3.2% 
 Vocational/technical school 4 12.9% 
 Some college 9 29.0% 
 Bachelor's degree 8 25.8% 
 Master's degree 8 25.8% 
 Doctoral degree 1 3.2% 
Household Income (N = 29) 
 $20,001 - 30,000 5 17.2% 
 $30,001 - 40,000 5 17.2% 
 $40,001 - 50,000 3 10.3% 
 $50,001 - 60,000 2 6.9% 
 $60,001 - 70,000 3 10.3% 
 $70,001 - 80,000 2 6.9% 
 Over $80,000 9 31.0% 
Marital Status (N = 31) 
 Single, never married 3 9.6% 
 Married or domestic partnership 27 87.0% 
 Divorced 1 3.2% 
Table 1: Demographic Characteristics 
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Dietary Iron RDA at Meeting One 
     Recall that the potential impact of dietary iron unrelated to capsule ingestion upon iron 
status is controlled for via the Willet FFQ. Participants generally split evenly into one of 
two categories: adequate or exceeds RDA for lactating women (9mg/day), with only one 
participant below RDA. However, 9mg/day is much lower than the recommendations for 
pregnant women of 27 mg/day (Khalafallah & Dennis, 2012). For this reason it was 
important to determine the annual average dietary iron intake of participants during week 
36 of pregnancy (Meeting 1) based upon the recommended daily allowance for pregnant 
women. Table 2 shows that an additional three participants were below RDA for pregnant 
women, splitting almost evenly among the three conditions: Experimental, Placebo, and 
Iron Groups.  
 
Week 36 of Pregnancy (Meeting 1) 
RDA for pregnant women (27 mg/day) 
 
Experimental 
(Placenta) 
Group Placebo Group Iron Group Total 
Below  
(<27 mg/day) 1 2 1 4 
Adequate 
(27-45 mg/day) 5 4 1 10 
Exceeds 
(>45mg/day) 5 10 1 16 
Total n = 11* n = 16 n = 3 n = 30 
Table 2: Week 36 of Pregnancy (Meeting 1): RDA for pregnant women (27 mg/day) 
 *One participant from the Experimental Group did not complete the Willet FFQ. 
 
Iron Status Analytes 
The reference ranges for each iron analyte (hemoglobin, transferrin, and ferritin 
respectively) are examined below, separated according to participant condition: 
Experimental (Placenta) Group, Placebo Group, and Iron Group. Reference ranges 
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classify participants into three analyte status categories: below, expected, and exceeds 
reference range (see Table 3). It is important to note that these categories do not represent 
‘iron deficient’ clinical diagnosis categories in the context of this study.  Such diagnoses 
should only be made by a licensed health care provider using standardized clinical 
procedures and laboratory methods. Rather, these categories are presented here for 
heuristic and comparative purposes only – based on manufacturer POC meter and 
laboratory assay reference ranges. For hemoglobin ranges, recall that the STAT-Site Hgb 
Meter expected values for adult females are 11.0-18.0 g/dL (Stanbio Laboratory, 2013). 
Expected transferrin values range between 202-364 mg/dL, with levels greater than 364 
indicating transferrin deficiency and levels lower than 202 indicating transferrin excess 
(Aquilani, et al., 2014). Expected ferritin values for women 17-60 years are 13-150 
mg/mL (Eaton, 2013). 
 
 HGB Transferrin Ferritin 
Below <11 g/dL >364 mg/dL <13 ng/mL 
Expected 11-18 g/dL 202-364 mg/dL 13-150 ng/mL 
Exceeds >18 g/dL <202 mg/dL >150 ng/mL 
Table 3: Expected Ranges for Iron Analytes 
 
Figures 1-3 categorize the Experimental (Placenta) Group (n=12), the Placebo Group 
(n=16), and the Iron Group (n=3) by hemoglobin, transferrin, and ferritin expected values 
(below and expected), as well as provide the number of participants for each expected 
value category and meeting. Tables 4-6 provide us with additional information on 
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averages for each meeting, subdivided by the status of the analyte (below, expected, and 
exceeds). Please note that no participant hemoglobin samples exceeded expected values, 
and therefore the exceeds category was not included in Figure 1 and Table 4. 
Hemoglobin 
From the data in Figure 1 and Table 4, we can see that below participants in the 
Experimental (Placebo) Group increase from Meeting 1 to 2. Following placenta 
supplement initiation, below values decrease across the next two meetings. No participant 
hemoglobin levels fall within the exceeds range for the Experimental Group.  
Participants from The Placebo Group with values below the reference range increase 
from Meeting 1 (two participants) to Meeting 2 (nine participants). Following placebo 
supplement initiation, values below the reference range decrease to one participant at 
Meeting 3, and zero participants at Meeting 4. No participant hemoglobin ranges fall 
within the exceeds range for this Placebo Group.  
All three participants from the Iron Group are within the expected hemoglobin range 
over the course of the four meetings, with no participants experiencing below or exceeds 
hemoglobin 
Transferrin 
For all three groups (Experimental, Placebo, and Iron) we can see that participants 
with values below the reference range decrease across the four meetings, participants 
with values in the expected reference range increases across the four meetings, and only 
two participants from the Placebo Group exceeds transferrin at Meeting 4 (Figure 2 and 
Table 5). 
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Ferritin 
     For all three groups, Figure 3 and Table 6 show that participants with ferritin values 
below the reference range generally decrease across all four meetings, excluding a slight 
uptick of one participant at Meeting 4 for the Experimental Group. The Iron Group had a 
single case of ferritin values below the reference range at Meeting 1, which resolved 
thereafter. The number of participants within the expected range generally increases 
across meetings for all groups; once again, however, the Experimental Group has a 
decrease by one participant from Meeting 3 (ten participants) to Meeting 4 (nine 
participants). Only one participant (PL-1032, from the Placebo Group) recorded an 
exceeds value for transferrin, which occurs across all four meetings.  
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Figure 1: Number of participants with hemoglobin levels in below and expected ranges, broken up by   
Condition. Note that no participant hemoglobin samples exceeded the expected range. 
 
Hemoglobin 
Group 
Analyte 
Status 
Meeting 1 Meeting 2 Meeting 3 Meeting 4 
N Mean N Mean N Mean N Mean 
Experimental 
(Placenta) 
below 3 10.38 6 8.88 5 9.44 3 9.53 
expected 9 12.38 6 11.65 7 12.62 9 13.34 
Placebo below 2 9.05 9 10.41 1 10.85 0 N/A expected 14 12.65 7 12.50 15 12.77 16 13.45 
Iron below 0 N/A 0 N/A 0 N/A 0 N/A expected 3 11.98 3 12.33 3 12.75 3 12.50 
Table 4: Number of participants and means of hemoglobin levels in below and expected ranges, 
broken up by Condition. Note that no participant hemoglobin samples exceeded the expected range. !
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Figure 2: Number of participants with transferrin levels in below, expected, and exceeds ranges, 
broken up by Condition. 
 
Transferrin 
Group 
Analyte 
Status 
Meeting 1 Meeting 2 Meeting 3 Meeting 4 
N Mean N Mean N Mean N Mean 
Experimental 
(Placenta) 
below 9 416.33 4 414.25 4 409.50 2 393.00 
expected 3 352.66 8 333.75 8 327.75 10 281.60 
exceeds 0 N/A 0 N/A 0 N/A 0 N/A 
Placebo 
below 5 435.60 3 420.00 3 408.66 0 N/A 
expected 11 329.09 13 303.61 13 295.38 14 272.57 
exceeds 0 N/A 0 N/A 0 N/A 2 188.50 
Iron 
below 2 485.50 1 510.00 1 511.00 0 N/A 
expected 1 347.00 2 317.00 2 309.50 3 278.33 
exceeds 0 N/A 0 N/A 0 N/A 0 N/A 
Table 5: Number of participants and means of transferrin levels in below, expected, and exceeds 
ranges, broken up by Condition. 
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Figure 3: Number of participants with ferritin levels in below, expected, and exceeds ranges, broken 
up by Condition. 
 
Ferritin 
Group 
Analyte 
Status 
Meeting 1 Meeting 2 Meeting 3 Meeting 4 
N Mean N Mean N Mean N Mean 
Experimental 
(Placenta) 
below 4 6.67 3 7.35 2 6.17 3 6.93 
expected 8 25.67 9 55.53 10 51.18 9 66.44 
exceeds 0 N/A 0 N/A 0 N/A 0 N/A 
Placebo 
below 5 8.60 2 9.11 1 8.89 1 12.00 
expected 10 23.45 13 40.02 14 41.12 14 54.46 
exceeds 1 160.00 1 236.00 1 347.00 1 289.00 
Iron 
below 1 7.86 0 N/A 0 N/A 0 N/A 
expected 2 21.68 3 39.63 3 48.73 3 67.26 
exceeds 0 N/A 0 N/A 0 N/A 0 N/A 
Table 6: Number of participants and means of ferritin levels in below, expected, and exceeds ranges, 
broken up by Condition.
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Deficiencies of Multiple Analytes at Corresponding Time Points 
Table 7 supplies a breakdown of participants who recorded sample values below the 
expected reference range for more than one analyte at corresponding time points. The 
Experimental (Placenta) Group had a greater amount of participants that began with 
values below the expected reference range for multiple analytes than did the 
Experimental (Placenta) Group. Twenty-five percent of Experimental Group participants 
were below the expected reference range in two out of three analytes at Meeting 1, 
compared to 13% of Placebo Group Participants. While 33% of Iron Group participants 
were below the expected reference range in two out of three analytes at Meeting 1, it is 
important to note that this percentage comprises a single participant (with a total of three 
Iron Group participants), and making comparisons to the other larger groups difficult.  
Seventeen percent of Experimental (Placenta) Group participants were below the 
expected reference range in three out of three analytes at Meeting 1, compared to 6% of 
Placebo Group Participants, and 0% of Iron Group participants. 
This initial disparity in iron analytes among groups will be important when further 
analyzing our results. 
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   Meeting 1 Meeting 2 Meeting 3 Meeting 4 
  Analytes: 
Hemoglobin, 
Transferrin, 
Ferritin 
Number of values below the expected reference range 
   2 of 3 3 of 3 2 of 3 3 of 3 2 of 3 3 of 3 2 of 3 3 of 3 
T
ot
al
 G
ro
up
 N
 
N = 12 Experimental 
(Placenta) 
Group N 3 2 1 2 1 2 0 2 
Experimental 
(Placenta) 
Group 
Percentage 25% 17% 8% 17% 8% 17% 0% 17% 
N = 16 Placebo Group 
N 2 1 1 1 0 0 0 0 
Placebo Group 
Percentage 13% 6% 6% 6% 0% 0% 0% 0% 
N = 3 Iron Group N 1 0 0 0 0 0 0 0 
Iron Group 
Percentage 33% 0% 0% 0% 0% 0% 0% 0% 
Table 7: Participants with sample values below the expected reference range for 2 of 3, or 3 of 3 
analytes at corresponding time points. 
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     The following three sections analyze iron levels assessed via hemoglobin, transferrin, 
and ferritin, whereas above, participants were separated into dietary iron status groups. 
 
Hemoglobin Results 
Analysis of hemoglobin data for Experimental (Placenta) and Placebo Groups, not 
controlling for dietary iron status, showed a statistically significant (p=0.000) change 
over time (Figure 4). There was a decrease in hemoglobin at Meeting 2, followed by an 
improvement in hemoglobin at Meeting 3 and a further improvement at Meeting 4.  
Hemoglobin pairwise comparisons for the Experimental Group using Bonferroni 
corrected post hoc tests show there were statistically significant differences between 
Meetings: 1 to 2 (p=0.048), 2 to 3 (p=0.005), 2 to 4 (p=0.000), and 3 to 4 (p=0.001). 
Likewise, hemoglobin pairwise comparisons for the Placebo Group using Bonferroni 
corrected post hoc tests show there were statistically significant differences between 
measures: 2 to 3 (p=0.001), and 2 to 4 (p=0.000). 
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Figure 4: Hemoglobin boxplots comparing Experimental (Placenta) Group and Placebo Group 
across meetings 1-4. 
    
However, the interaction of hemoglobin and condition was not significant (p=0.276).  
In other words, the hemoglobin of Experimental and Placebo Groups changed over time, 
but changed in similar ways. Figure 5 shows the parallel movement of hemoglobin status 
over time. We see that the groups have parallel lines that decrease from Meetings 1 to 2, 
and then increase steadily afterward (indicating hemoglobin status improvement). 
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Figure 5: Hemoglobin Estimated Marginal Means comparing Experimental (Placenta) Group and 
Placebo Group across meetings 1-4. 
 
 The difference in mean hemoglobin values between the Experimental and Placebo 
Groups at any time point simply represents the different average baseline levels for the 
two groups.  In addition, between-subjects effects show that the average difference 
between Experimental and Placebo Groups was not statistically significant (p=0.059). 
The majority of Experimental and Placebo Group participants were grouped into 
adequate dietary iron status or exceeds RDA recommendations for iron intake among 
lactating women (19 – 50 y) based upon the results of their Willet FFQ responses. Eleven 
participants had a daily average iron intake between 9-45 mg/day, or adequate dietary 
iron intake. Fifteen participants had a daily average iron intake over 45 mg/day, or 
exceeds dietary iron intake. Four participants fell below the RDA iron intake 
recommendations (Table 2).  A Mixed ANOVA was completed controlling for these 
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dietary groups, with no statistical differences shown between dietary controls and the 
hemoglobin results. 
 
Transferrin Results 
Analysis of transferrin data for Experimental (Placenta) and Placebo Groups, not 
controlling for dietary iron status, showed a statistically significant (p=0.000) change 
over time (Figure 6). There was a steady improvement of iron status as estimated from 
plasma transferrin, over time (note that lowering transferrin levels indicate improved iron 
status).  
Transferrin pairwise comparisons for the Experimental Group using Bonferroni 
corrected post hoc tests show there were statistically significant differences between 
Meetings: 1 to 3 (p=0.04), 1 to 4 (p=0.000), 2 to 4 (p=0.005), and 3 to 4 (p=0.001). 
Transferrin pairwise comparisons for the Placebo Group using Bonferroni corrected post 
hoc tests show there were statistically significant differences between measures: 1 to 2 
(p=0.002), 1 to 3 (p=0.000), 1 to 4 (p=0.000), 2 to 4 (p=0.000), and 3 to 4 (p=0.000). 
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Figure 6: Transferrin boxplots comparing Experimental (Placenta) Group and Placebo Group across 
meetings 1-4.              
 
The interaction of transferrin and condition was not significant (p=0.986). As with 
hemoglobin, the transferrin values of Experimental and Placebo Groups changed over 
time, but changed in similar ways. Figure 7 shows the parallel movement of transferrin 
status over time. We see that the groups have parallel lines that decrease steadily through 
Meetings 1 to 4 (indicating transferrin status improvement). Once again, differences in 
transferrin values for the Experimental and Placebo Groups reflected different baseline 
levels which were not affected by either the experimental or placebo conditions. 
Between-subjects effects show that the average difference between Experimental and 
Placebo Groups was not statistically significant (p=0.052).   
As with hemoglobin, a Mixed ANOVA was used to control for iron dietary groups 
(adequate and exceeds). There was only one difference shown between transferrin (n=28), 
! 48 
and transferrin_adequate (n=11). The between-groups test for transferrin of all dietary 
groups indicates that the variable condition (Experimental vs. Placebo) is not significant 
(p=0.052), consequently, in Figure 7 we see that the lines for the two groups are close 
together. The between-groups test for transferrin_adequate indicates that the 
variable condition (Experimental vs. Placebo) is significant (p=0.037), consequently in 
Figure 8 we see that the lines for the two groups are a bit apart (especially in comparison 
to Figure 7). This means that transferrin_adequate conditions (Experimental and Placebo) 
started off at statistically significant different points. Recall that Mixed ANOVAs showed 
no statistical differences between dietary controls and hemoglobin results. This 
underlines the importance of assessing multiple analytes (in this study: hemoglobin, 
transferrin, and ferritin) to garner a more accurate understanding of iron status. 
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Figure 7: Transferrin Estimated Marginal Means comparing Experimental (Placenta) Group and 
Placebo Group across meetings 1-4, for all dietary transferrin groups (n=28).     
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Figure 8: Transferrin Estimated Marginal Means comparing Experimental (Placenta) Group and 
Placebo Group across meetings 1-4, for Adequate Dietary Group (n=11) 
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Ferritin Results 
Analysis of ferritin data for Experimental (Placenta) and Placebo Groups, not 
controlling for dietary iron status, required a Log10 transformation to normalize the data. 
Figure 9 shows the ferritin boxplots prior to Log10 transformation, and Figure 10 shows 
the normalized data. 
 
 
Figure 9: Ferritin boxplots comparing Experimental (Placenta) Group and Placebo Group across 
meetings 1-4, prior to Log10 transform.  
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Figure 10: Ferritin boxplots comparing Experimental (Placenta) Group and Placebo Group across 
meetings 1-4, after Log10 transform.   
 
Normalized ferritin data reveals a statistically significant (p=0.000) change (Figure 
10). There was a steady increase of ferritin over time, indicating improved iron status. 
However, the interaction of ferritin and condition was not significant (p=0.751).  As with 
the two other biomarkers for iron status in the study, ferritin of Experimental and Placebo 
Groups changed over time, but changed in similar ways. Figure 11 shows the parallel 
movement of ferritin status. We see that the groups have parallel lines that increase 
steadily from Meetings 1 to 4 (indicating ferritin status improvement). In addition, 
between-subjects effects reveal that the average difference in ferritin values between 
Experimental and Placebo Groups was not statistically significant (p=0.357).   
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Figure 11: Ferritin Estimated Marginal Means comparing Experimental (Placenta) Group and 
Placebo Group across meetings 1-4. 
             
Ferritin pairwise comparisons for the Experimental Group using Bonferroni corrected 
post hoc tests show there were statistically significant differences between Meetings: 1 to 
2 (p=0.026), and 1 to 3 (p=0.003). Pairwise comparisons for the Placebo Group using 
Bonferroni corrected post hoc tests show there were statistically significant differences 
between Meetings: 1 to 2 (p=0.000), 1 to 3 (p=0.000), and 1 to 4 (p=0.000). 
Once again, a Mixed ANOVA was used to control for iron dietary groups (adequate 
and exceeds). No statistical differences were shown between iron dietary groups and 
overall ferritin results. 
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Pearson’s r Correlation 
Pearson’s r Correlation was utilized to calculate correlations among variables within 
each time period. The following are statistically significant (p<0.10) correlations from 
both conditions (Experimental and Placebo Groups), broken up by meeting time. 
 
Meeting 1 
 
Transferrin to Ferritin Hemoglobin to Ferritin 
Effect p-value Effect p-value 
Experimental 
(Placenta) 
Strong, 
negative 
(r = -0.680) 
0.015   
Placebo   
Positive, 
moderate 
(r = 0.533) 
0.033 
Table 8: Meeting 1 Pearson’s r Correlation by Condition 
Meeting 2 
 
Transferrin to Ferritin 
Effect p-value 
Experimental 
(Placenta) 
Negative, 
strong 
(-0.762) 
0.004 
Placebo 
Negative, 
moderate 
(-0.449), 
0.081 
Table 9: Meeting 2 Pearson’s r Correlation by Condition 
Meeting 3 
 Transferrin to Ferritin 
Transferrin to 
Hemoglobin 
Hemoglobin to 
Ferritin 
Effect p-value Effect p-value Effect p-value 
Experimental 
(Placenta) 
Negative, 
strong 
(-0.837) 
0.001 
Positive, 
strong 
(0.667) 
0.018   
Placebo 
Negative, 
strong 
(-0.589) 
0.016   
Positive, 
moderate 
(0.495) 
0.051 
Table 10: Meeting 3 Pearson’s r Correlation by Condition 
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Meeting 4 
 Transferrin to Ferritin 
Transferrin to 
Hemoglobin 
Hemoglobin to 
Ferritin 
Effect p-value Effect p-value Effect p-value 
Experimental 
(Placenta) 
Negative, 
strong 
(-0.868), 
0.000 
Negative, 
strong 
(-0.821) 
0.001 
Positive, 
strong 
(0.799), 
0.002 
Placebo 
Negative, 
strong 
(-0.572), 
0.021     
  Table 11: Meeting 4 Pearson’s r Correlation by Condition 
 
Analytes from Meetings 2 through 4 correlate similarly across conditions. The effect 
size and correlation of transferrin to ferritin is similar for each condition: negatively 
correlated with a moderate to strong effect. As transferrin decreases, ferritin increases. 
This makes sense, as transferrin will lower and ferritin will rise with improved iron status. 
This is further indication that a great deal of difference between Experimental and 
Placebo Groups may not exist. 
 
Iron Group 
The small sample size (n=3) of the Iron Group will not enable comparative statistical 
analyses to be conducted with the Experimental and Placebo Groups. Instead, descriptive 
statistics for this data are examined to garner a general idea of Iron Group results and 
how they might compare given a more robust sample size.  
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Figure 12: Hemoglobin means for meetings 1-4 by Condition. 
 
 
Hemoglobin 
Condition Meeting 1 Meeting 2 Meeting 3 Meeting 4 
 Mean SD Mean SD Mean SD Mean SD 
Iron 11.98 0.80 12.33 0.93 12.75 1.00 12.50 0.93 
Placenta 11.88 1.11 10.27 1.84 11.29 2.11 12.39 1.97 
Placebo 12.20 1.79 11.33 1.17 12.66 1.20 13.45 0.90 
Table 12: Hemoglobin means and Standard Deviations for meetings 1-4 by Condition. 
 
 
Figure 13: Transferrin means for meetings 1-4 by Condition. Note that transferrin deficiency is 
indicated by greater than values. 
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Transferrin 
Condition Meeting 1 Meeting 2 Meeting 3 Meeting 4 
 Mean SD Mean SD Mean SD Mean SD 
Iron 439.33 129.20 381.33 113.00 376.67 118.00 278.33 57.18 
Placenta 400.42 49.65 362.00 52.00 355.00 51.60 300.16 51.71 
Placebo 362.37 62.60 325.44 58.40 316.62 56.20 262.06 46.02 
Table 13: Transferrin means and Standard Deviations for meetings 1-4 by Condition. 
 
 
 
Figure 14: Ferritin means for meetings 1-4 by Condition. 
 
Ferritin 
Condition Meeting 1 Meeting 2 Meeting 3 Meeting 4 
 Mean SD Mean SD Mean SD Mean SD 
Iron 17.08 14.68 39.63 25.00 48.73 17.40 67.26 61.36 
Placenta 19.34 14.75 46.05 40.70 43.68 35.10 51.57 47.00 
Placebo 27.34 36.52 48.41 52.60 58.23 78.40 66.47 66.82 
Table 14: Ferritin means and Standard Deviations for meetings 1-4 by Condition. 
 
For the Iron Group, excluding hemoglobin, the means of transferrin and ferritin for 
each meeting generally trend the same as the Experimental Group and the Placebo Group. 
Due to the Iron Group’s small sample size, it is not possible to draw any conclusions 
based on statistical analysis. However, from these iron supplement group comparisons, 
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the data are consistent with this study’s null hypotheses (1a, 1b, and 1c), that the 
Experimental Group would not show a greater interval increase in iron levels (assessed 
via hemoglobin, transferrin, and ferritin) as compared to Placebo and Iron Group 
participants from: (1a) baseline (within 72 hours postpartum) to day five-seven 
postpartum, (1b) baseline to week three postpartum, and (1c) days five-seven postpartum 
to week three postpartum. 
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CHAPTER 6 
 
DISCUSSION 
Hypotheses Revisited 
Hypothesis 1: Supported 
Experimental, Placebo, and Iron Group participants showed an increase in iron 
levels (assessed via hemoglobin, transferrin, and ferritin) measured during, (a) days five-
seven postpartum, and (b) week three postpartum, as compared to baseline measure 
taken prior to supplement initiation (within 72 hours postpartum). 
Hypothesis 1a: Rejected 
Experimental Group participants did not show a greater interval increase in iron 
levels (assessed via hemoglobin, transferrin, and ferritin) as compared to Placebo Group 
and Iron Group participants from baseline (within 72 hours postpartum) to day five-
seven postpartum. 
Hypothesis 1b: Rejected 
Experimental Group participants did not show a greater interval increase in iron 
levels (assessed via hemoglobin, transferrin, and ferritin) as compared to Placebo Group 
and Iron Group participants from baseline to week three postpartum. 
Hypothesis 1c: Rejected 
Experimental Group participants did not show a greater interval increase in iron 
levels (assessed via hemoglobin, transferrin, and ferritin) as compared to Placebo Group 
and Iron Group participants from days five-seven postpartum to week three postpartum. 
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Data analyses support Hypothesis 1 and fail to support the Null Hypothesis. The 
statistical analyses conducted to test Hypotheses 1a, 1b, and 1c support the Null 
Hypotheses and fail to support Hypotheses 1a, 1b, and 1c. The Iron Group failed to 
recruit a sufficient amount of participants to address this group’s role in Hypotheses 1a, 
1b, and 1c via statistical analysis. 
 
Public Health Implications 
Placentophagy is a growing practice in the Las Vegas Valley and has been spreading 
within industrialized countries since the 1960s (Young & Benyshek, 2010). High profile 
celebrities are engaging in this practice, and television programs have featured 
placentophagy, thereby increasing its public visibility and introducing millions of women 
to a practice that has not been subjected to rigorous scientific evaluation with respect to 
its potential health benefits and/or risks.  
If some women forgo traditional postpartum iron supplementation in favor of 
placenta supplementation, it is necessary that any iron present in those supplements be in 
a bioavailable form and in sufficient amounts to meet the increased iron demands 
associated with pregnancy and nursing. Iron deficiency and IDA are associated with 
negative health outcomes for both mother and child, making this issue particularly 
important. Unfortunately, this study was not able to assess the effect of encapsulated 
placenta supplementation on the iron status of postpartum mothers suffering from 
clinically diagnosed iron deficiency or IDA. The current study’s results do suggest, 
however, that encapsulated placenta supplementation neither significantly improves, nor 
! 61 
significantly impairs postpartum maternal iron status for women consuming at least 
adequate amounts of dietary iron postpartum1. 
 
Limitations 
 Given the recruitment limitations associated with a double-blind placebo-controlled 
study centered upon the ingestion of a participant’s own placenta, the participant sample 
was, as a matter of necessity, self-selecting; not every pregnant women will want to 
ingest their placenta postpartum. Therefore, the Experimental and Placebo Groups used 
in this study consisted of a self-selecting population, making true randomization 
impossible.  
Samples sizes for Experimental and Placebo Groups could have been more robust, 
however the sample sizes were large enough to conduct statistical analyses and draw 
conclusions about differences and similarities between the two groups. The Iron Group’s 
low sample size (n=3) prevented similar statistical comparisons among all three groups. 
Instead, Iron Group data were examined as case studies. Due to this we were unable to 
address portions of this study’s research questions related to the efficacy of placenta 
supplementation in comparison to standard iron supplements regarding recovery from 
postpartum iron deficiency.  
The gold-standard for hemoglobin measurement is the direct cyanmethaemoglobin 
method analyzed via spectrophotometer. This method, however, requires processing of 
samples within a few hours of collection as well as access to an appropriately equipped 
laboratory (Sari, et al., 2001). Given these constraints, the POC STAT-Site Hemoglobin !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!Only one participant from our sample had an average daily dietary intake of iron below 
RDA recommendations during lactation.!
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Meter is an excellent alternative. POC tools are essential for immediate bedside care of 
patients, and are extremely convenient when used to conduct medical anthropological 
field research. The accuracy of the STAT-Site Hemoglobin meter is dependent upon the 
use of blood drops of a particular volume, however. The STAT-Site meter will give 
erroneous results for drops smaller than 10µL and larger than 30µL (Stanbio Laboratory, 
2013). Both slight variation in blood collection technique among project researchers, and 
variation in the hydration of participants effecting ease of blood flow may lead to 
differences in the size of blood drops collected and therefore hemoglobin results. In order 
to reduce this error, whenever possible, two drops were collected and averaged. 
For this study, blood samples were collected via finger-stick lancet. Generally, 
venous blood draws are a more commonly used collection method, and most ranges for 
analytes are based upon venous blood as opposed to finger-stick capillary blood samples. 
As mentioned in Chapter 4, capillary blood differs from venous blood in a number of 
ways and affects some, but not all, analytes. In the case of this study, ranges for expected 
hemoglobin status were included with the STAT-Site Hemoglobin meter, which are 
already adapted for capillary blood samples. Transferrin and ferritin ranges, however, are 
not adapted to the collection method used in this study. Lu et al. (1987) reports that 
capillary ferritin values may be about 7% higher than venous values. Another study 
shows that capillary plasma overestimates ferritin by 8.9% in adults when compared to 
venous plasma (Mejia & Viteri, 1983). All blood samples from this study were collected 
via finger-stick capillary method. Given that iron status was not included in the 
participant selection criteria, and that one of the primary goals of this study was to make 
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relative comparisons between groups, obtaining laboratory values precise enough for 
diagnostic purposes (e.g., IDA), were not necessary. 
Some methods used to analyze data gathered from the Willet FFQ favored the 
possibility of overestimation of participant dietary iron status. For example, some 
questions on the Willet FFQ presented participants with a selection of similar foods, but 
required a single answer for that grouping; one entry asked the frequency of consumption 
of peaches, apricots, or plums. In cases such as these, each item’s iron content was 
investigated using the USDA National Nutrient Database. The food item with the highest 
iron content, controlling for portion size, was always chosen. The use of such methods 
may lead to the overcompensation of dietary iron, however, it is preferable to 
overestimate dietary iron contributions rather than potentially falsely attribute the 
fluctuations of hemoglobin, transferrin, and ferritin to supplement ingestion. 
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CHAPTER 7 
 
CONCLUSION AND RECOMMENDATIONS 
Pregnancy, birth, and the postpartum period present considerable physiological 
challenges to women. Iron deficiency is often a byproduct of the demands associated with 
human reproduction. Iron deficiency can be particularly problematic for women with 
high IBIs, those who do not exclusively breastfeed, are obese, or are low income 
individuals (Allen, 2000; Bodnar, Siega-Riz, Miller, Cogswell, & McDonald, 2002). Iron 
deficiency can also negatively affect the children of iron deficient mothers (Rasmussen, 
2001; Lewis et al., 2002; Golub, Hogrefe, Germann, Capitanio, & Lozoff, 2006; Colomer, 
1990). Currently, many maternal placentophagy advocates claim that encapsulated 
placenta is an excellent source of iron for postpartum mothers (Selander et al., 2013). To 
date, however, there have been no rigorous scientific studies that have investigated this 
claim. 
The results of this study help fill major gaps of knowledge in the practice of human 
maternal placentophagy. The current study suggests that encapsulated placenta 
supplementation neither significantly improves, nor impairs postpartum maternal iron 
status for women consuming at least adequate amounts of dietary iron. It is possible that 
participants’ placenta was not necessarily a superior source of iron than a beef or soy-free 
vegetarian placebo supplement of the same daily intake. This may mean that, among 
women with adequate dietary iron intake, the bioavailability of iron present in the 
placebo supplement is roughly equal to the bioavailability of iron in the placenta 
supplement. 
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OTC oral iron supplements are commonly used by women around the world, and are 
of particular importance for pregnant and postpartum women experiencing iron 
deficiency and IDA. One of the original goals of this study was to examine how placenta 
supplements compared to standard oral iron supplements in order to deduce whether 
placenta supplements are a viable option for the restoration of women’s iron status 
postpartum, as this alternative form of iron supplementation may appeal to many mothers 
looking for a more “natural” way to manage postpartum iron deficiency. While the small 
size of the OTC iron supplement group served only as case studies for comparison to the 
study’s Placenta and Placebo groups, it appears that, among women with adequate dietary 
iron intake, encapsulated placenta supplements offer neither a superior, nor inferior, 
source of oral iron supplementation. Unfortunately, the question of whether placenta 
supplements are superior, equal, or inferior to standard iron supplements for women with 
postpartum iron deficiency or IDA was beyond the scope of this study. 
Future research might include focusing upon clinically diagnosed iron deficient and 
IDA participants. Such studies would allow researchers to examine how well 
encapsulated placenta supplements compare to traditional iron supplements among 
women whose iron status is the most severely compromised. In addition to such clinical 
studies, the research of placentophagy would benefit from the ethnographic study of 
women engaging in placentophagy as well as placentophagy advocates. Such 
ethnographies could examine topics such as women’s motivations for engaging in 
placentophagy, and maternal health decision-making. 
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Background Information Questionnaire 
An Investigation of the Effects of Human Maternal Placentophagy in Postpartum 
Maternal Health and Recovery 
University of Nevada, Las Vegas 
 
Please answer the following questions as accurately as possible  
Age: _____   Height: _____ ft ______ in  Weight: _____ lbs 
With which ethnicity do you most closely identify?  
__ American Indian/Alaska Native  __ Caucasian    __ Middle Eastern  
__ Asian     __ Hispanic/Latina   __ Other ___________  
__ African American    __ Hawaiian/Pacific Islander  
What is the highest level of education you have completed?  
__ Grammar School      __ Bachelor’s degree       __ Doctoral degree  
__ High School or equivalent    __ Master’s degree          __ Professional degree (MD, JD, etc.)  
__ Some college      __ Vocational/technical school  
Which of the following income groups includes your total annual family income:  
__ Under $10,000   __ $30,001—$40,000   __ $60,001—$70,000  
__ $10,000—$20,000   __ $40,001—$50,000  __ $70,001—$80,000  
__ $20,001—$30,000  __ $50,001—$60,000  __ Over $80,000  
Please indicate your marital status: 
__ Single, never married  __ Married or domestic partnership 
__ Separated __ In a committed relationship, not cohabiting 
__ Divorced __ Widowed 
Total number of people in the household: _____  
Zip Code: _______________ 
Do you currently consume alcoholic beverages?  Yes   No  
 If yes, how often (circle one)?  daily frequently      occasionally rarely 
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Do you currently smoke cigarettes?   Yes   No  
In the 3 months before your most recent pregnancy, did you take a multivitamin 
containing folic acid or a folic acid supplement?  
Never  Rarely  Occasionally   Almost every day  Daily 
Is this your first pregnancy?  Yes  No 
If this is not your first pregnancy, how many times have you given live birth? ___  
Please list the dates that you have given live birth:   
  MM  /  DD  /  YYYY  .   MM  /  DD  /  YYYY  .   MM  /  DD  /  YYYY  . 
  MM  /  DD  /  YYYY  .   MM  /  DD  /  YYYY  .   MM  /  DD  /  YYYY  . 
  MM  /  DD  /  YYYY  .   MM  /  DD  /  YYYY  .   MM  /  DD  /  YYYY  . 
Did you have complications with any of your pregnancies?   Yes   No    
If yes, please explain briefly: 
________________________________________________________________________
________________________________________________________________________ 
Have you ever ingested placenta, in any form, after any of your pregnancies?  Yes        No 
 If yes, after which pregnancy did you ingest placenta? ______________________ 
Did you experience any effects that you attributed to placentophagy?   Yes        No 
 Please describe: ____________________________________________________ 
            __________________________________________________________________ 
Have you been diagnosed with, or do you suspect you may have an iron-related disorders 
(e.g., hemochromatosis, iron deficiency, iron deficiency anemia)?      Yes  No 
 If yes, was this condition diagnosed by a medical practitioner?   Yes No 
If yes, please describe: _______________________________________________ 
            __________________________________________________________________ 
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Do you have any chronic health conditions?   Yes  No 
 If yes, please describe them here: ______________________________________ 
 __________________________________________________________________ 
 __________________________________________________________________ 
Have you received a blood transfusion within the past year?          Yes  No 
 If yes, when did you receive the most recent transfusion?     MM  /   YY  .   
Are you currently consuming a special diet (e.g., vegan, vegetarian, etc.)?  Yes         No  
If yes, please explain: ________________________________________________ 
__________________________________________________________________ 
Did your diet changed after learning that you were pregnant? Yes  No 
 If yes, please explain how? 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________ 
 How much has your diet changed since pre-pregnancy (circle one)? 
  drastically  moderately  minimally  none 
Are you currently taking any medications?   Yes   No  
If yes, please list the medication(s) you are taking: _________________________ 
__________________________________________________________________
__________________________________________________________________ 
Are you currently taking any nutritional supplements (including multivitamins): Yes   No  
If yes, please list them here, and indicate the brand and dose: ________________ 
__________________________________________________________________ 
__________________________________________________________________ 
__________________________________________________________________ 
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Please mark any of the following conditions that you have experienced, and indicate the 
severity and whether the condition was diagnosed by a medical professional: 
___ Depression Mild  Moderate Severe ___ Diagnosed  
___ 
Antenatal (pregnancy) 
depression 
Mild  Moderate Severe ___ Diagnosed  
___ Postnatal depression Mild  Moderate Severe ___ Diagnosed  
___ Maternity blues Mild  Moderate Severe ___ Diagnosed  
___ 
Premenstrual dysphoric 
disorder (PMDD) 
Mild  Moderate Severe ___ Diagnosed  
___ Anxiety Mild  Moderate Severe ___ Diagnosed  
___ Bipolar disorder Mild  Moderate Severe ___ Diagnosed  
___ Schizophrenia Mild  Moderate Severe ___ Diagnosed  
___ Anemia Mild  Moderate Severe ___ Diagnosed  
___ Insomnia/sleep disorder Mild  Moderate Severe ___ Diagnosed  
___ Thyroid disorder Mild  Moderate Severe ___ Diagnosed  
___ Endocrine disorder Mild  Moderate Severe ___ Diagnosed  
___ 
Reproductive disorder (e.g., 
PCOS, endometriosis) 
Mild  Moderate Severe ___ Diagnosed  
Do you have an allergy or sensitivity to Ferrous sulfate (iron)? Yes  No  
What is the starting date of your last menstrual period?    MM  /  DD  /  YY      
What is your projected due date?    MM  /  DD  /  YY     
Where do you plan to give birth?  
__ In a hospital with a physician   __ At home     
__ In a hospital with a midwife    __ At a birthing center    
__ Other  Please describe: _________________________________________ 
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Biomedical IRB – Full Board Review 
Approval Notice 
 
NOTICE TO ALL RESEARCHERS: 
Please be aware that a protocol violation (e.g., failure to submit a modification for any 
change) of an IRB approved protocol may result in mandatory remedial education, 
additional audits, re-consenting subjects, researcher probation, suspension of any 
research protocol at issue, suspension of additional existing research protocols, 
invalidation of all research conducted under the research protocol at issue, and further 
appropriate consequences as determined by the IRB and the Institutional Officer. 
 
DATE:  July 23, 2013 
 
TO:   Dr. Daniel Benyshek, Anthropology 
 
FROM:  Office of Research Integrity - Human Subjects  
 
RE:   Notification of IRB Action 
Protocol Title: An Investigation of the Effects of Human Maternal 
Placentophagy on Postpartum Health and Recovery 
Protocol #: 1305-4465M 
Expiration Date: July 22, 2014  
________________________________________________________________________ 
 
This memorandum is notification that the project referenced above has been reviewed 
and approved by the UNLV Biomedical Institutional Review Board (IRB) as indicated in 
Federal regulatory statutes 45 CFR 46 and UNLV Human Research Policies and 
Procedures. 
  
The protocol is approved for a period of one year and expires July 22, 2014. If the above-
referenced project has not been completed by this date you must request renewal by 
submitting a Continuing Review Request form 60 days before the expiration date.  
 
PLEASE NOTE:  
Upon approval, the research team is responsible for conducting the research as stated in 
the protocol most recently reviewed and approved by the IRB, which shall include using 
the most recently submitted Informed Consent/Assent forms and recruitment materials. 
The official versions of these forms are indicated by footer which contains approval and 
expiration dates.  
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Should there be any change to the protocol, it will be necessary to submit a Modification 
Form through ORI - Human Subjects. No changes may be made to the existing protocol 
until modifications have been approved by the IRB. Modified versions of protocol 
materials must be used upon review and approval. Unanticipated problems, deviations to 
protocols, and adverse events must be reported to the ORI – HS within 10 days of 
occurrence.  
 
If you have questions or require any assistance, please contact the Office of Research 
Integrity - Human Subjects at IRB@unlv.edu or call 895-2794.  
 
 
Office of Research Integrity - Human Subjects 
4505 Maryland Parkway • Box 451047 • Las Vegas, Nevada 89154-1047 
(702) 895-2794 • FAX: (702) 895-0805 
  ! !
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Biomedical IRB – Expedited Review  
Continuing Review Approved 
 
NOTICE TO ALL RESEARCHERS: 
Please be aware that a protocol violation (e.g., failure to submit a modification for any 
change) of an IRB approved protocol may result in mandatory remedial education, 
additional audits, re-consenting subjects, researcher probation suspension of any 
research protocol at issue, suspension of additional existing research protocols, 
invalidation of all research conducted under the research protocol at issue, and further 
appropriate consequences as determined by the IRB and the Institutional Officer. 
 
DATE:  June 19, 2014  
TO:   Dr. Daniel Benyshek, Anthropology  
FROM:  Office of Research Integrity – Human Subjects  
RE:  Notification of IRB Action 
Protocol Title: An Investigation of the Effects of Human Maternal 
Placentophagy on Postpartum Health and Recovery 
Protocol #: 1305-4465M 
Expiration Date: June 18, 2015  
________________________________________________________________________ 
 
Continuing review of the protocol named above has been reviewed and approved.  
 
This IRB action will reset your expiration date for this protocol. The protocol is approved 
for a period of one year from the date of IRB approval. The new expiration date for this 
protocol is June 18, 2015. If the above-referenced project has not been completed by this 
date you must request renewal by submitting a Continuing Review Request form 30 days 
before the expiration date.  
 
PLEASE NOTE:  
Upon approval, the research team is responsible for conducting the research as stated in 
the protocol most recently reviewed and approved by the IRB, which shall include using 
the most recently submitted Informed Consent/Assent forms and recruitment materials. 
The official versions of these forms are indicated by footer which contains current 
approval and expiration dates. 
  
Should there be any change to the protocol, it will be necessary to submit a Modification 
Form through ORI - Human Subjects. No changes may be made to the existing protocol 
until modifications have been approved by the IRB. Modified versions of protocol 
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materials must be used upon review and approval. Unanticipated problems, deviations to 
protocols, and adverse events must be reported to the ORI – HS within 10 days of 
occurrence. 
 
If you have questions or require any assistance, please contact the Office of Research 
Integrity - Human Subjects at IRB@unlv.edu or call 895-2794. 
  
 
Office of Research Integrity - Human Subjects 
4505 Maryland Parkway • Box 451047 • Las Vegas, Nevada 89154-1047 
(702) 895-2794 • FAX: (702) 895-0805 
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